HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Helen Usansky Selected Research

PF-06263507

1/2021ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Helen Usansky Research Topics

Disease

1Bronchiectasis
01/2022
1Neoplasms (Cancer)
01/2021
1Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome)
12/2012

Drug/Important Bio-Agent (IBA)

1brensocatibIBA
01/2022
1Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA
01/2022
1Serine Proteases (Serine Protease)IBA
01/2022
1AntigensIBA
01/2021
1Immunoconjugates (Immunoconjugate)IBA
01/2021
1Pharmaceutical PreparationsIBA
01/2021
1Glycoproteins (Glycoprotein)IBA
01/2021
1PF-06263507IBA
01/2021
1Ado-Trastuzumab EmtansineIBA
01/2021
1Nitric Oxide (Nitrogen Monoxide)FDA Link
12/2012